home All News open_in_new Full Article

Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease

Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease  MarketWatch


today 16 h. ago attach_file Economics

attach_file Events
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Science


ID: 3792506804
Add Watch Country

arrow_drop_down